--- canonical_url: https://www.stockexpertai.com/earnings/ctva last_updated: 2026-05-05T21:11:39.069Z --- # Corteva, Inc. (CTVA) Q1 FY2026 Earnings Preview > **[stale-preview-note]** Note: this preview was published before the 2026-05-05 earnings report. Results have since been released — verify against the latest filings. > This content was automatically generated with FMP live data + Q4 FY2025 earnings call transcript. Generated: 2026-05-05T21:11:38.780Z. Educational tool, not investment advice. --- ## Quick Summary | Field | Value | Source | |---|---|---| | Price | $83.91 (▲ 2.72%) | fmp:quote | | Market Cap | $56.3B | fmp:profile | | 52w range | $60.53 – $85.63 | fmp:quote | | Earnings | Tue 5 May | fmp:earnings-history | | EPS estimate | $1.18 (+4% YoY) | fmp:earnings-estimate | | Revenue estimate | $4.6B | fmp:earnings-estimate | | Beat streak | 0/4 | fmp:earnings-history | | Rating | B+ (overall 3/5) | fmp:ratings | | Analyst median target | $88 (+4.9% upside) | fmp:price-target-consensus | | MoonshotScore | 36/100 | derived | | Council | 2/6 bullish | derived | | Munger verdict | Fairly Valued | derived | ## Corteva, Inc. — Q1 FY2026 Expectations Q1 consensus: revenue $4.6B^{[FMP est]}, EPS $1.18^{[FMP est]}. 0 consecutive quarters of beat^{[FMP earnings]}. ## Quick Take **Score:** B+ · **Stance:** HOLD · **Council:** 2/6 · **Moonshot:** 36 = MoonshotScore 36^{[9-pillar formula]} + Council 2/6^{[6-lens rule]}. Form 4: 0 transactions^{[FMP Form 4]}. ## Watchlist (4 metrics) ### 1. 2026 EBITDA Growth Corteva expects approximately 7% operating EBITDA growth for 2026. > "2026 operating EBITDA is expected to be in the range of $4 billion and $4.2 billion or approximately 7% improvement over prior year at the midpoint." > — David Johnson, Executive Vice President and Chief Financial Officer, Investor Focus · Q4 FY2025 ### 2. Bayer Resolution Earnings Upside Corteva believes the agreement with Bayer will generate about $1 billion of aggregate earnings upside for Corteva across their corn, cotton, and canola portfolios over the next 10 years. > "However, over the course of the next 10 years, we believe this agreement will generate about $1 billion of aggregate earnings upside for Corteva across our corn, cotton and canola portfolios through both out-licensing and branded sales." > — Charles Magro, Chief Executive Officer, Investor Focus · Q4 FY2025 ### 3. Royalty Neutrality Acceleration Corteva now expects to achieve royalty neutrality in 2026, which is 2 years ahead of their most recent expectations. > "As a result of this resolution and the progress we've been making across the broader out-licensing spectrum, we now expect to achieve royalty neutrality in 2026, which is 2 years ahead of our most recent expectations." > — Charles Magro, Chief Executive Officer, Investor Focus · Q4 FY2025 ### 4. H1 2026 Sales EBITDA Concentration Corteva is expecting about 60% of sales and roughly 85% of EBITDA to be delivered in the first half of the year. > "Regarding the timing of sales and earnings in 2026, we are expecting about 60% of sales and roughly 85% of EBITDA to be delivered in the first half of the year." > — David Johnson, Executive Vice President and Chief Financial Officer, Investor Focus · Q4 FY2025 ## MoonshotScore Pillars | Pillar | Score | Level | Evidence | |---|---|---|---| | Revenue Growth | 0.0 | weak | Q1 vs Q2: growth negative (-24.0%, contraction) | | Gross Margin | 0.0 | weak | Q1: low margin (0.0%, capital-intensive or commodity) | | Operating Leverage | 1.0 | weak | op margin average (14.8%) | | Cash Runway | 3.0 | weak | FCF negative ($-3.0B, external financing needed) | | R&D Intensity | 7.0 | strong | balanced R&D investment (8.5%) | | Price Momentum | 7.0 | strong | RSI 64.3 positive momentum, 50d above | | News Sentiment | 7.0 | strong | majority buy (68%) | **Formula:** sum(pillar.score) / (count * 10) * 100. Each pillar deterministic from FMP. Source maps in pillar.formula. ## Council (7-Lens) | Name | Stance | Context | |---|---|---| | Ray Dalio | bull | macro · target upside +4.9% | | Ken Griffin | bull | flow · 50d MA above | | Jim Simons | neutral | quant · RSI 64 | | Klarman | neutral | value · target upside +4.9% | | Buffett | neutral | quality · ROE score 3/5 | | Munger | neutral | valuation · target upside +4.9% | **Formula:** Each lens uses deterministic rule on bundle data. Logged in member.contextTr. ## Munger Lens - **Verdict:** Fairly Valued - **Financial Health:** Moderate - **Margin of Safety:** Weak - **Interest Coverage:** Adequate - **ROIC vs WACC:** Tight **Formula:** verdict=upside>25?Undervalued:>0?Fairly Valued:Overvalued. Each lens deterministic from FMP ratings + priceTarget. ## Technical Levels - **RSI(14):** 64.3 — yükselişte nötr — overbought sınırının altında, momentum pozitif - **50d MA:** $81 — hisse %4.2 üstünde — kısa vadeli destek - **200d MA:** $72 — hisse %16.8 üstünde — uzun vadeli destek - **Volume (10d):** +62% ## Past Performance (4 Quarters) | Quarter | EPS Actual | EPS Estimate | Result | Reaction | |---|---|---|---|---| | Q1 FY25 | $1.13 | $0.87 | BEAT | +7.0% | | Q2 FY25 | $2.20 | $1.89 | BEAT | -0.2% | | Q3 FY25 | $-0.23 | $-0.51 | BEAT | +1.9% | | Q4 FY25 | $0.22 | $0.22 | +-1.3% EPS | +0.1% | Q4 (February 4, 2026): EPS $0.22 vs $0.22 est^[FMP], +-1.3% beat. D+1 movement: +0.1%^{[FMP D+1]}. Decline despite beat — market reacted to guidance, not numbers. ## 3 Scenarios ### Scenario A · Beat **Q1 EPS > $1.18 + CapEx discipline** Threshold: EPS > $1.18^{[FMP est]}. Target: Break above median target $88^{[FMP target]}; high target $95^[FMP] upper bound. ### Scenario B · In-Line **EPS ≈ $1.18 + CapEx < $81.0M** Threshold: EPS ≈ $1.18^{[FMP est]}, Q1 CapEx < $81.0M^[FMP]. Target: Consolidation in the band between current $84^[FMP] and median $88^[FMP]. ### Scenario C · Miss **EPS < $1.14 or CapEx ≥ $81.0M** Threshold: EPS < $1.14^{[FMP est×0.97]}. Target: Current $84 below SMA200 $72^[FMP], if rejection continues, $61^[derived] support activates. ## Risk Notes ### Primary segment below threshold Q4: EPS $0.22 vs $0.22 beat^[FMP], stock +0.1% D+1^[FMP]. ### Backlog concentration No RPO/backlog concentration disclosed in Q4 earnings call. ### Insider trading Form 4 data is marked in the table — this page does not generate assumptions for this stock. | Executive | Action | Amount | Date | |---|---|---|---| **Net:** — (0 transactions · 0 sells · 0 buys) · Q4 FY25 ### CapEx shock Q4 CapEx $81.0M^{[FMP cashflow]}. Q4 op margin 14.8%^{[FMP op margin]} — this level in Q1 is sensitive to CapEx revision risk. ## Wall Street Consensus - **Median target:** $88 (+4.9% upside vs current $84) - **High / Low:** $95 / $82 - **Buy / Hold / Sell:** 15 / 7 / 0 - **Analyst count:** 5 (last quarter), 51 all-time ## Additional Transcript Insights ### 1. 2026_EBITDA_Growth **Claim:** Corteva expects approximately 7% operating EBITDA growth for 2026. **Evidence (transcript):** "2026 operating EBITDA is expected to be in the range of $4 billion and $4.2 billion or approximately 7% improvement over prior year at the midpoint." **Numbers:** 7%, $4 billion, $4.2 billion ### 2. Royalty_Neutrality_Acceleration **Claim:** Corteva now expects to achieve royalty neutrality in 2026, which is 2 years ahead of their most recent expectations. **Evidence (transcript):** "As a result of this resolution and the progress we've been making across the broader out-licensing spectrum, we now expect to achieve royalty neutrality in 2026, which is 2 years ahead of our most recent expectations." **Numbers:** 2026, 2 ### 3. Bayer_Resolution_Earnings_Upside **Claim:** Corteva believes the agreement with Bayer will generate about $1 billion of aggregate earnings upside for Corteva across their corn, cotton, and canola portfolios over the next 10 years. **Evidence (transcript):** "However, over the course of the next 10 years, we believe this agreement will generate about $1 billion of aggregate earnings upside for Corteva across our corn, cotton and canola portfolios through both out-licensing and branded sales." **Numbers:** 10, $1 billion ### 4. Crop_Protection_Volume_Growth **Claim:** Corteva expects Crop Protection volume to be up mid-single digits in 2026, driven by demand for new products and biologicals. **Evidence (transcript):** "Crop Protection volume is expected to be up mid-single digits, driven by demand for new products and biologicals, which are expected to outperform the rest of the portfolio." **Numbers:** — ### 5. Seed_Volume_Flat_2026 **Claim:** Corteva expects volumes to be relatively flat in Seed as North America share gains are expected to be offset by the corn to soy planted area shift, and have a full year under their Brazil soybean shift to licensing. **Evidence (transcript):** "We are expecting volumes to be relatively flat in Seed as North America share gains are expected to be offset by the corn to soy planted area shift, and have a full year under our Brazil soybean shift to licensing." **Numbers:** — ### 6. H1_2026_Sales_EBITDA_Concentration **Claim:** Corteva is expecting about 60% of sales and roughly 85% of EBITDA to be delivered in the first half of the year. **Evidence (transcript):** "Regarding the timing of sales and earnings in 2026, we are expecting about 60% of sales and roughly 85% of EBITDA to be delivered in the first half of the year." **Numbers:** 60%, 85% --- *Data source: FMP (live query, 2026-05-05), Q4 FY2025 earnings call transcript (Translated to EN with Gemini 2.0 Flash). Educational tool, not investment advice.*